Skip to content
MARKETS / NASDAQ / NUWE
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Nuwellis, Inc. NUWE

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$8.3M
▼ 5.4% YoY
$-17.5M
$-10.9M
In brief

What this company does

The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”). Please note that selected authors in the citations below are either current consultants to the Company or were previously compensated consultants. We provide healthcare professionals with a reliable, predictable, and easy-to-use mechanical pump and filtration system to remove excess fluid from fluid overloaded patients. We believe that our technology will provide a competitive advantage in the fluid management market by providing improved clinical benefits and reducing the cost of care relative to other treatment alternatives.

Written from the business description in Nuwellis, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 March 2026. Every sentence was checked against that document before publication.

Growth
USD 8.3M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 8.3 · Net income -17.5
4M8M-10M-20M20112013201520172019202120232025
Compound annual growth
−1.1%
+2.1%
+63.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−212 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -134.3% · Net -211.9%
-20000%-40000%20112013201520172019202120232025
ROE
FY2025 · ROE -382.9%
-200%-400%20112013201520172019202120232025

Each USD of equity lost 383 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -10.9
-8M-16M20112013201520172019202120232025

Total assetsUSD 6.1M
EquityUSD 2.6M
CashUSD 1.1M
Current ratio1.71×

Equity funds 43% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0·−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−25.39−353.30−360.06−83.55−285.36−10.67−278.90−42.14−525.01−536.12−44.01−1.51−1.71−1.98−2.98
Dividend / sh $···············
Payout %···············
ROE %−382.9−234.6−263.4−75.8−92.5−173.0−457.1−153.6−148.7−226.8·····
Shares out B0.000.000.000.000.000.000.000.000.000.000.000.020.020.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 25 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image